Cytotoxic functions and susceptibility to apoptosis of human CD56 bright NK cells differentiated in vitro from CD34 + hematopoietic progenitors

Cytometry Part A

Volumn 81 A, Issue 4, 2012, Pages 294-302

  Zamai, Loris ^a,b   Del Zotto, Genny ^a   Buccella, Flavia ^a   Galeotti, Laura ^a   Canonico, Barbara ^a   Luchetti, Francesca ^a   Papa, Stefano ^a  

^a UNIVERSITY OF URBINO   (Italy)

^b LABORATORI NAZIONALI DEL GRAN SASSO   (Italy)

Author keywords

Apoptosis; Cell differentiation; Cellular activation; Cytotoxicity; NK cells

Indexed keywords

CD34 ANTIGEN; CD56 ANTIGEN; INTERLEUKIN 15;

ADULT; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CYTOLOGY; HEMATOPOIETIC STEM CELL; HUMAN; METABOLISM; NATURAL KILLER CELL; UPREGULATION;

ADULT; ANTIGENS, CD34; ANTIGENS, CD56; APOPTOSIS; CELL DIFFERENTIATION; HEMATOPOIETIC STEM CELLS; HUMANS; INTERLEUKIN-15; KILLER CELLS, NATURAL; UP-REGULATION;

EID: 84858797879     PISSN: 15524922     EISSN: 15524930     Source Type: Journal    
DOI: 10.1002/cyto.a.22025     Document Type: Article

References (41)

1. Bottino C, Moretta L, Pende D, Vitale M, Moretta A. Learning how to discriminate between friends and enemies, a lesson from Natural Killer cells. Mol Immunol 2004; 41: 569-575.
2. Farag SS, Caligiuri MA. Human natural killer cell development and biology. Blood Rev 2006; 20: 123-137.
3. Mirandola P, Ponti C, Gobbi G, Sponzilli I, Vaccarezza M, Cocco L, Zauli G Secchiero P, Manzoli FA, Vitale M. Activated human NK and CD8+ T cells express both TNF-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors but are resistant to TRAIL-mediated cytotoxicity. Blood 2004; 104: 2418-2424.
4. Zamai L, Ponti C, Mirandola P, Gobbi G, Papa S, Galeotti L, Cocco L, Vitale M. Natural killer cells and cancer. J Immunol 2007; 178: 4011-4016.
5. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol 2001; 22: 633-640.
6. André P, Spertini O, Guia S, Rihet P, Dignat-George F, Braille H, Sampol J, Anderson PJ, Vivier E. Modification of P-selectin glycoprotein ligand-1 with a natural killer cell-restricted sulfated lactosamine creates an alternate ligand for L-selectin. Proc Natl Acad Sci U S A 2000; 97: 3400-3405.
7. bright natural killer cells. Immunity 2005; 22: 295-304.
8. Sivori S, Cantoni C, Parolini S, Marcenaro E, Conte R, Moretta L, Moretta A. IL-21 induces both rapid maturation of human CD34+ cell precursors towards NK cells and acquisition of surface killer Ig-like receptors. Eur J Immunol 2003; 33: 3439-3447.
9. Parrish-Novak J, Dillon SR, Nelson A, Hammond A, Sprecher C, Gross JA, Johnston J, Madden K, Xu W, West J, et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 2000; 408: 57-63.
10. Sivori S, Falco M, Marcenaro E, Parolini S, Biassoni R, Bottino C, Moretta L, Moretta A. Early expression of triggering receptors and regulatory role of 2B4 in human natural killer cell precursors undergoing in vitro differentiation. Proc Natl Acad Sci USA 2002; 99: 4526-4531.
11. Bennett IM, Zatsepina O, Zamai L, Azzoni L, Mikheeva T, Perussia B. Definition of a natural killer NKR-P1A+/CD56-/CD16- functionally immature human NK cell subset that differentiates in vitro in the presence of interleukin 12. J Exp Med 1996; 184: 1845-1856.
12. Freud AG, Caligiuri MA. Human natural killer cell development. Immunol Rev 2006; 214: 56-72.
13. Nagler A, Lanier LL, Cwirla S, Phillips JH. Comparative studies of human FcRIII-positive and negative natural killer cells. J Immunol 1989; 143: 3183-3191.
14. Takahashi E, Kuranaga N, Satoh K, Habu Y, Shinomiya N, Asano T, Seki S, Hayakawa M. Induction of CD16+ CD56bright NK cells with antitumour cytotoxicity not only from CD16- CD56bright NK Cells but also from CD16- CD56dim NK cells. Scand J Immunol 2007; 65: 126-138.
15. Raulet DH, Vance RE. Self-tolerance of natural killer cells. Nat Rev Immunol 2006; 6: 520-531.
16. Zamai L, Ahmad M, Bennett IM, Azzoni L, Alnemri ES, Perussia B. Natural killer (NK) cell-mediated cytotoxicity: Differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J Exp Med 1998; 188: 2375-2380.
17. Freud AG, Yokohama A, Becknell B, Lee MT, Mao HC, Ferketich AK, Caligiuri MA. Evidence for discrete stages of human natural killer cell differentiation in vivo. J Exp Med 2006; 203: 1033-1043.
18. - immature human NK cell subset. Cytometry A 2009; 75: 893-901.
19. Zamai L, Canonico B, Luchetti F, Ferri P, Melloni E, Guidotti L, Cappellini A, Cutroneo G, Vitale M, Papa S. Supravital exposure to propidium iodide identifies apoptosis on adherent cells. Cytometry 2001; 44: 57-64.
20. Briard D, Brouty-Boyé D, Azzarone B, Jasmin C. Fibroblasts from human spleen regulate NK cell differentiation from blood CD34(+) progenitors via cell surface IL-15. J Immunol 2002; 168: 4326-4332.
21. Kasaian MT, Whitters MJ, Carter LL, Lowe LD, Jussif JM, Deng B, Johnson KA, Witek JS, Senices M, Konz RF, et al. IL-21 limits NK cell responses and promotes antigen-specific T cell activation: A mediator of the transition from innate to adaptive immunity. Immunity 2002; 16: 559-569.
22. - bone marrow cells. J. Immunol 2003; 171: 683-690.
23. Grzywacz B, Kataria N, Sikora M, Oostendorp RA, Dzierzak EA, Blazar BR, Miller JS, Vernerie MR. Coordinated acquisition of inhibitory and activating receptors and functionalproperties by developing human natural killer cells. Blood 2006; 108: 3824-3833.
24. Cooley S, Xiao F, Pitt M, Gleason M, McCullar V, Bergemann TL, McQueen KL, Guethlein LA, Parham P, Miller JS. A subpopulation of human peripheral blood NK cells that lacks inhibitory receptors for self-MHC is developmentally immature. Blood 2007; 110: 578-586.
25. Nowbakht P, Ionescu MC, Rohner A, Kalberer CP, Rossy E, Mori L, Cosman D, De Libero G, Wodnar-Filipowicz A. Ligands for natural killer cell-activating receptors are expressed upon the maturation of normal myelomonocytic cells but at low levels in acute myeloid leukemias. Blood 2005; 105: 3615-3622.
26. Loza MJ, Zamai L, Azzoni L, Rosati E, Perussia B. Expression of type 1 (interferon gamma) and type 2 (interleukin-13, interleukin-5) cytokines at distinct stages of natural killer cell differentiation from progenitor cells. Blood 2002; 99: 1273-1281.
27. Zamai L, Secchiero P, Pierpaoli S, Bassini A, Papa S, Alnemri ES, Guidotti L, Vitale M, Zauli G. TNF-related apoptosis-inducing ligand (TRAIL) as a negative regulator of normal human erythropoiesis. Blood 2000; 95: 3716-3724.
28. Secchiero P, Gonelli A, Mirandola P, Melloni E, Zamai L, Celeghini C, Milani D, Zauli G. Tumor necrosis factor-related apoptosis-inducing ligand induces monocytic maturation of leukemic and normal myeloid precursors through a caspase-dependent pathway. Blood 2002; 100: 2421-2429.
29. Ferlazzo G, Thomas D, Lin SL, Goodman K, Morandi B, Muller WA, Moretta A, Münz C. The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic. J Immunol 2004; 172: 1455-1462.
30. dim NK cells upon activation. J Immunol 2007; 178: 4947-4955.
31. Huntington D, Legrand N, Alves NL, Jaron B, Weijer K, Plet A, Corcuff E, Mortier E, Jacques Y, Spits H, Di Santo JP. IL-15 trans-presentation promotes human NK cell development and differentiation in vivo. J Exp Med 2009; 206: 25-34.
32. Dulphy N, Haas P, Busson M, Belhadj S, Peffault de Latour R, Robin M, Carmagnat M, Loiseau P, Tamouza R, et al. An unusual CD56(bright) CD16(low) NK cell subset dominates the early posttransplant period following HLA-matched hematopoietic stem cell transplantation. J Immunol 2008; 181: 2227-2237.
33. dim cells: Role of contact with peripheral fibroblasts. J Immunol 2007; 179: 89-94.
34. Vosshenrich CA, García-Ojeda ME, Samson-Villéger SI, Pasqualetto V, Enault L, Richard-Le Goff O, Corcuff E, Guy-Grand D, Rocha B, Cumano A, et al. A thymic pathway of mouse natural killer cell development characterized by expression of GATA-3 and CD127. Nat Immunol 2006; 7: 1217-1224.
35. Allan DSJ, Rybalov B, Awong G, Zúñiga-Pucker JC, Kopcow HD, Carlyle JR, Strominger JL. TGF-beta affects development and differentiation of human natural killer cell subsets. Eur J Immunol 2010; 40: 2289-2295.
36. Carson WE, Giri JG, Lindemann MJ, Linett ML, Ahdieh M, Paxton R, Anderson D, Eisenmann J, Grabstein K, Caligiuri MA. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med 1994; 180: 1395-1403.
37. Wendt K, Wilk E, Buyny S, Schmidt RE, Jacobs R. Interleukin-21 differentially affects human natural killer cell subsets. Immunology 2007; 122: 486-495.
38. Strbo N, de Armas L, Liu H, Kolber MA, Lichtenheld M, Pahwa S. IL-21 augments natural killer effector functions in chronically HIV-infected individuals. AIDS 2008; 22: 1551-1560.
39. Jacobs R, Stoll M, Stratmann G, Leo R, Link H, Schmidt RE. CD16- CD56+ natural killer cells after bone marrow transplantation. Blood 1992; 79: 3239-3244.
40. Shilling, HG, McQueen KL, Cheng NW, Shizuru JA, Negrin RS, Parham P. Reconstitution of NK cell receptor repertoire following HLA-matched hematopoietic cell transplantation. Blood 2003; 101: 3730-3740.
41. Koehne G, Zeller W, Stockschlaeder M, Zander AR. Phenotype of lymphocyte subsets after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1997; 19: 149-156.